Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (171-180 of 223) with videos related to

Pageof 23
Sort By:
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
Blood|July 10, 2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapyFarhad Ravandi, Jeffrey L Jorgensen, Deborah A Thomas, et al.
Blood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
British Journal of Haematology|February 12, 2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemiaWilliam G Wierda, John C Byrd, Susan O'Brien, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Pageof 23

Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
Blood|July 10, 2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapyFarhad Ravandi, Jeffrey L Jorgensen, Deborah A Thomas, et al.
Blood|February 21, 2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
British Journal of Haematology|February 12, 2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemiaWilliam G Wierda, John C Byrd, Susan O'Brien, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Pageof 23